Non-opioid painkiller developer Latigo (LTGO.US) aims to take advantage of the biotechnology IPO "tailwind"! Issuing price set at $18 per share, planning to raise $346 million.

Latigo Biotherapeutics, a biotechnology company focused on developing non-opioid therapies for acute and chronic pain, which is nearing the entry into phase three clinical trials, has priced its initial public offering (IPO) in the U.S. at $18 per share, at the high end of the previously announced pricing range of $16 to $18. The company plans to issue 19.2 million shares (increasing the final offering size by 27% from the original plan) to raise $346 million. It intends to list on NASDAQ under the ticker symbol "LTGO." Latigo is dedicated to developing non-opioid pain medications targeting the Nav1.8 sodium ion channel. Its core candidate, LTG-001, is an oral Nav1.8 inhibitor primarily aimed at treating moderate to severe acute pain, including postoperative pain. This drug is designed to provide analgesic effects comparable to opioids while avoiding the risk of addiction. Nav1.8 is primarily expressed in peripheral pain-sensing neurons, and its inhibitors do not act on the central nervous system, thus eliminating the potential for addiction. Previously released clinical data showed that in a randomized, placebo- and active-controlled phase 2b trial involving 343 postoperative abdominal surgery patients, LTG-001 achieved the primary endpoint of SPID48 (the sum of pain intensity differences over 48 hours), with all key secondary endpoints showing high statistical significance. This represents the highest reported analgesic effect in this pain model for any drug. In the high-dose LTG-001 group, 52% of patients did not use opioid rescue medication during treatment, compared to only 22% in the placebo group. Regarding time to onset, the median time to effect for LTG-001 was 51.7 minutes, faster than Vicodin. In January 2025, Vertex Pharmaceuticals Incorporated's (VRTX.US) similar drug, Journavx (suzetrigine), received approval from the U.S. Food and Drug Administration (FDA), becoming the world's first approved Nav1.8 inhibitor, validating the druggability and regulatory pathway for this target. Latigo acknowledged in its prospectus that Journavx "is limited by efficacy, slow onset, and contraindications," while LTG-001 aims to differentiate itself by addressing these shortcomings. Latigo plans to conduct a placebo-controlled phase 3 clinical trial of LTG-001 for patients undergoing thumb bunionectomy in the second half of 2026, as well as an open-label phase 3 safety trial, with top-line results expected to be announced in the second half of 2027. Additionally, Latigo's second Nav1.8 candidate, LTG-321, targets chronic musculoskeletal pain, initially indicated for osteoarthritis, and is currently undergoing a phase 2 proof-of-concept clinical trial, with results also expected to be announced in the second half of 2027. The company's early R&D pipeline also includes the preclinical Nav1.8 inhibitor LTG-418, and other early-stage projects targeting ion channels involved in pain signaling. Financially, Latigo has yet to achieve profitability. It reported a net loss of $61.2 million in 2024, with the net loss projected to expand to $109.2 million in 2025, primarily due to research and development expenses ($99.5 million in 2025) and general administrative expenses ($10.86 million). The company previously stated that the net proceeds from this IPO, combined with existing resources, would be sufficient to support its operating expenses and capital expenditure needs until the second half of 2028. It is worth noting that Latigo's decision to go public comes at a prime time for biotech IPOs. Data shows that since 2026, the weighted average return on IPOs of U.S. biotech and pharmaceutical companies has reached as high as 55%, while the overall IPO market, excluding SPACs, has averaged a loss of 4.4%. The biotech sector has outperformed the broader market by nearly 60 percentage points, making it the biggest winner in the U.S. IPO market in 2026. Data indicates that 18 biotech companies completed IPOs in the first half of 2026, more than double the total number for 2025 (8 companies). Year-to-date in 2026, newly listed biotech and pharmaceutical companies have raised a cumulative $5.4 billion, compared to only $969.2 million in the same period last year. The factors driving this wave of biotech IPOs include the sustained rise of the NASDAQ Biotechnology Index, a relatively stable FDA approval environment, and strong investor interest in platform companies with differentiated clinical data and clear market opportunities. Latigo's IPO is expected to take advantage of this favorable climate, potentially opening up room for its stock price to rise.